Promising Advancements in enGene Holdings’ Clinical Trials Justify Buy Rating
I'm PortAI, I can summarize articles.
H.C. Wainwright analyst Andres Y. Maldonado has maintained a Buy rating on enGene Holdings, setting a price target of $25.00, citing promising advancements in clinical trials. The Phase 2 LEGEND trial data shows improved response rates for detalimogene voraplasmid in treating high-risk, BCG-unresponsive non-muscle invasive bladder cancer. The treatment's safety, ease of use, and competitive pricing enhance its market potential. Additionally, Raymond James upgraded the stock to a Buy with a $27.00 price target, reflecting confidence in its future success.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments